Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in Journal of American Heart Association

summarizeSummary

Cardiol Therapeutics announced that its positive Phase II MAvERIC study results for CardiolRx™ in recurrent pericarditis have been accepted for publication in the Journal of the American Heart Association, providing significant independent validation for its ongoing Phase III trial.

check_boxKey Events

• Phase II MAvERIC Results Accepted for Publication

  Results from the Phase II MAvERIC study evaluating CardiolRx™ for recurrent pericarditis have been accepted for publication in the Journal of the American Heart Association.

• Clinical Findings Highlighted

  The peer-reviewed publication details rapid and sustained reductions in pericarditis pain and inflammation, a substantial reduction in recurrence episodes, and a favorable safety profile for CardiolRx™.

• Validation for Ongoing Phase III Trial

  These positive Phase II findings provide important independent validation and clinical rationale for the ongoing pivotal Phase III MAVERIC trial, which recently surpassed 75% enrollment.

auto_awesomeAnalysis

The acceptance of Cardiol Therapeutics' Phase II MAvERIC study results for publication in a prestigious peer-reviewed journal like the Journal of the American Heart Association is a significant positive development. This independent validation of CardiolRx™'s efficacy and safety in reducing pericarditis pain and inflammation, coupled with a favorable safety profile, strengthens the clinical rationale for the ongoing pivotal Phase III MAVERIC trial. The publication reinforces the potential for CardiolRx™ as a differentiated, non-immunosuppressive therapy and de-risks the development pathway, which is crucial for a late-stage life sciences company.